The third phase of clinical trials of the ZF-UZ-VAC2001 coronavirus vaccine showed an overall efficacy of 81.76% for all strains, the Ministry of Innovative Development reported.
The vaccine efficacy after the third dose was 81.76% for all strains and 92.93% against the “British” strain. It has shown 100% effective against deaths and severe cases. According to WHO requirements, the vaccine must show an efficiency of at least 50%.
A total of 28,500 volunteers were enrolled in the ZF-UZ-VAC2001 clinical trials worldwide, of which 14,249 received the vaccine and 14,251 received a placebo. On August 20 this year, Chinese partners published data on vaccine and placebo groups. 647 of these volunteers were diagnosed with coronavirus, 221 of them – 7 days after receiving 3 doses of the vaccine. 35 of the cases received the vaccine, and 186 received a placebo. This shows that the vaccine was 81.76% effective against all strains of the coronavirus.
According to the WHO protocol, after full vaccination, at least 156 cases of the disease must be identified in order to publish the results of phase 3 and conduct statistical analysis. The results of the Phase III clinical trials of the ZF-UZ-VAC2001 vaccine were determined based on the analysis of 221 participants with the identified disease, which guarantees a more accurate research result.
For comparison, the Pfizer vaccine was 85% effective, AstraZeneca – 68%, while the Moderna vaccine showed high efficacy for the “primary” strain (Wuhan – 94%) and dropped to 76% for the “delta” strain.
Phase III of an international multicenter clinical trial of a vaccine began on December 10, 2020 and reached a total of 29,000 people over the age of 18. The studies were carried out in Hunan Province (China), as well as in Uzbekistan, Indonesia, Pakistan and Ecuador. Clinical trials in Uzbekistan are conducted by 8 specialists from Zhifei Longcom Biopharmaceutical Co. Ltd, 30 scientists from the Center for Advanced Technologies of the Ministry of Innovative Development, 112 medical workers from the Research Institute of Virology of the Health Ministry and other medical institutions.
A total of 6966 volunteers from Uzbekistan took part in clinical trials, 214 of whom are over 60 years old. During the study, each volunteer was vaccinated on a vaccine/placebo regimen with 3 doses at 28-day intervals. 13 of them reported moderate side effects, which is less than 0.002%. A sufficient amount of antibodies was found in 95% of cases in certain groups.
